Welcome to our dedicated page for HALOZYME THERAPEUTICS SEC filings (Ticker: HALO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on HALOZYME THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into HALOZYME THERAPEUTICS's regulatory disclosures and financial reporting.
Halozyme Therapeutics insider Bernadette Connaughton has filed to potentially sell 1,626 shares of common stock through Morgan Stanley Smith Barney LLC, with an indicated aggregate market value of $167,673.12 on NASDAQ as of a planned sale date of August 10, 2026. These shares relate to Restricted Stock Units granted on April 25, 2025. The filing also lists prior sales under a Rule 10b5-1 trading plan, including 1,625 shares sold on July 1, 2026 for $124,650.66 and 1,625 shares sold on June 1, 2026 for $107,591.25.
Halozyme Therapeutics, Inc., a biopharmaceutical company focused on ENHANZE and auto‑injector drug‑delivery technologies, reported the following results for the three and six months ended June 30, 2026. Total revenues were $480,999 thousand for the quarter and $857,707 thousand for the first half. Quarterly net income was $229,913 thousand, with diluted EPS of $1.90; six‑month net income was $379,962 thousand and diluted EPS $3.11.
Net cash provided by operating activities reached $420,969 thousand in the first half of 2026, while the company repurchased $332,729 thousand of common stock. At June 30, 2026, cash and cash equivalents were $163,138 thousand, available‑for‑sale marketable securities $67,865 thousand and restricted cash $848 thousand. Total assets were $2,577,408 thousand and total liabilities $2,433,865 thousand, including a current portion of long‑term debt of $208,970 thousand and long‑term debt, net, of $1,937,684 thousand.
Stockholders’ equity was $143,543 thousand, supported by retained earnings of $151,259 thousand. Halozyme continues to grow a royalty‑ and product‑driven model through ENHANZE collaborations, Hypercon and Surf Bio hyperconcentration technologies, and device partnerships, while integrating the 2025 Elektrofi acquisition to broaden its portfolio of drug‑delivery platforms.
Halozyme Therapeutics reported record second quarter 2026 results, with total revenue up 48% year-over-year to $481.0 million and royalty revenue up 50% to $307.7 million, driven mainly by ENHANZE partner products such as VYVGART Hytrulo and DARZALEX SC. Operating income reached $287.7 million and net income was $229.9 million. GAAP diluted EPS was $1.90 and Non-GAAP diluted EPS was $2.28. Adjusted EBITDA increased to $328.8 million.
The company raised its 2026 outlook, guiding to total revenue of $1.835–$1.910 billion (31%–37% growth), royalty revenue of $1.220–$1.245 billion (41%–43% growth), adjusted EBITDA of $1.225–$1.280 billion (86%–95% growth) and Non-GAAP diluted EPS of $8.65–$9.00 (108%–117% growth). Halozyme returned capital by repurchasing 4.8 million shares for $332.8 million in the quarter under its buyback programs and expanded its ENHANZE and Hypercon collaboration portfolio through new agreements with partners including GSK, Incyte, Vertex and Oruka.
Halozyme Therapeutics President and CEO Helen Torley exercised stock options for 1,923 shares of common stock at $12.07 per share and immediately sold the same 1,923 shares in open‑market transactions at prices around $79–$80 per share. These trades were carried out under a pre‑arranged Rule 10b5-1 trading plan adopted on March 21, 2025, and involved options that were due to expire in February 2027. After these transactions, Torley directly holds 767,780 shares of Halozyme common stock.
HALOZYME THERAPEUTICS EVP David A. Ramsay reported a series of equity compensation transactions. On July 1, 2026 he received an option to buy 39,823 shares of common stock at $77.01 per share and a grant of 16,232 restricted stock units.
On June 30, 2026 10,000 restricted stock units vested and were settled in common shares, with 5,408 shares withheld by the company to cover tax obligations and 4,592 shares remaining directly owned. The filing shows routine grants, vesting, and tax withholding rather than open-market trading.
HALOZYME THERAPEUTICS, INC. reported that SVP and Chief Financial Officer Darren Snellgrove received new equity awards on July 1, 2026. He was granted options to purchase 127,432 shares of common stock at an exercise price of $77.01 per share, along with 41,554 restricted stock units (RSUs).
The options begin vesting one-fourth on the first vesting date and then in equal monthly installments over 48 months, while the RSUs vest in three equal annual installments starting on the first anniversary of the grant date. These are compensation-related grants, not open‑market purchases or sales, and increase the CFO’s potential future ownership if vesting and exercise conditions are met.
HALOZYME THERAPEUTICS, INC. director Bernadette Connaughton reported open-market sales of a total of 1,625 shares of common stock. The trades were executed at weighted average prices of about $76 to $77 per share across two price ranges.
The sales were made under a pre-arranged written trading plan adopted on May 29, 2025 in accordance with Rule 10b5-1, indicating these transactions were scheduled in advance as part of ongoing portfolio management rather than discretionary timing decisions.
Halozyme Therapeutics, Inc. reported a senior leadership change. On June 30, 2026, the company announced an update to its senior management structure and the departure of Cortney Caudill from her role as Senior Vice President and Chief Operating Officer. The company publicly expressed appreciation for Ms. Caudill’s contributions during her tenure.
HALOZYME THERAPEUTICS, INC. director Mahesh Krishnan reported an exercise-and-sale transaction in company stock. He exercised options to acquire 7,304 shares of common stock at $38.46 per share, then sold 7,304 shares in an open-market transaction at $75.00 per share.
After these transactions, he holds 14,462 common shares directly and 1,500 options to purchase common stock. The filing states the option exercise and related sale were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 19, 2026, indicating the timing was set in advance.